Key Takeaways Mesenchymal stem cells are among the most studied cell types for chronic liver disease, but the approach is still experimental. Researchers think the cells may calm the immune system and slow scar-forming cells, mostly based on lab and animal work. Small human trials reported better survival in some
Key Takeaways Researchers test stem cell therapies for heart failure, but no trial shows that the cells rebuild a damaged heart. A 2016 Cochrane review of 38 trials and 1,907 people found no gain in heart pumping strength and rated the evidence low quality. A 2012 trial of 30 people
Quick Summary A 2026 Nature study (MATCH trial) shows autologous macrophage therapy may improve transplant‑free survival in cirrhosis. After 4 years, ~70% of treated patients were alive without liver transplant vs. ~40% in standard care. The treatment uses the patient’s own immune cells (macrophages) to reduce inflammation and support repair.
